Page last updated: 2024-11-09

4,6-dimethyl-2-thiopyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,6-dimethyl-2-thiopyrimidine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID673664
CHEMBL ID1650609
SCHEMBL ID51447
MeSH IDM0067876

Synonyms (68)

Synonym
HMS1766L06
einecs 244-911-3
4,6-dimethyl-2-thiopyrimidine
4,6-dimethyl-2(1h)-pyrimidinethione
2(1h)-pyrimidinethione, 4,6-dimethyl-
4,6-dimethylpyrimidine-2-thione
BB 0218011
nsc15491
2(1h)-pyrimidinethione,6-dimethyl-
22325-27-5
nsc-15491
4,6-dimethyl-2-mercaptopyrimidine ,
4,6-dimethyl-2-pyrimidinethiol
2-mercapto-4,6-dimethylpyrimidine
2-pyrimidinethiol,6-dimethyl-
nsc-314274
nsc-314273
AKOS000269270
D1580
4,6-dimethylpyrimidine-2-thiol
AKOS000119130
4,6-dimethyl-1h-pyrimidine-2-thione
CHEMBL1650609
4,6-dimethyl-pyrimidine-2-thiol
nsc 15491
unii-ygt3zq6lzp
ygt3zq6lzp ,
STK392544
2-mercapto-4,6-dimethyl-pyrimidine
FT-0688927
FT-0617264
AB01319403-02
SCHEMBL51447
AM81324
4,6dimethyl-2-mercaptopyrimidine
4,6 dimethyl-2-mercaptopyrimidine
4, 6dimethyl-2-mercaptopyrimidine
4,6-dimethyl-2-mercapto-pyrimidine
4, 6-dimethyl-2-mercaptopyrimidine
2-pyrimidinethiol, 4,6-dimethyl-
J-640155
J-650335
2-pyrimidinethiol, 4,6-dimethyl- (9ci)
131321-42-1
AC-26754
DTXSID70176867
J-514103
J-800158
4,5-dimethylpyrimidine-2(1h)-thione
GS-6774
4,6-dimethyl-1,2-dihydropyrimidine-2-thione
SY021364
mfcd00272876
4,6-dimethylpyrimidine-2(1h)-thione
F2130-0006
BCP24727
4,6-dimethyl-2-mercatopyrimidine
mfcd00006079
NCGC00324881-01
SB56806
SB57257
2-thio-4,6-dimethylpyrimidine
4,6-dimethyl-2-pyrimidinethione
4,6-dimethyl-2-pyrimidinylmercaptan
EN300-24824
4.6-dimethyl-2-mercaptopyrimidine
CS-W016454
Z203045050
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's5 (62.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]